248 related articles for article (PubMed ID: 36652173)
1. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
2. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
3. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
Spratt DE; George DJ; Shore ND; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown BA; Lu S; Fallick M; Hanson S; Tombal BF
JAMA Oncol; 2024 May; 10(5):594-602. PubMed ID: 38451492
[TBL] [Abstract][Full Text] [Related]
5. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Shore ND; Mehlhaff BA; Cookson MS; Saltzstein DR; Tutrone R; Brown B; Lu S; Fallick M; Hanson S; Saad F
Adv Ther; 2023 Nov; 40(11):4919-4927. PubMed ID: 37713020
[TBL] [Abstract][Full Text] [Related]
6. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer.
Saad F; Shore ND
Ther Adv Med Oncol; 2021; 13():1758835921998586. PubMed ID: 34408793
[TBL] [Abstract][Full Text] [Related]
7. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
[TBL] [Abstract][Full Text] [Related]
8. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
9. Relugolix in the management of prostate cancer.
Sahu KK; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
[TBL] [Abstract][Full Text] [Related]
10. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
[TBL] [Abstract][Full Text] [Related]
11. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
Shore ND; Sutton J
Future Oncol; 2022 Jul; 18(21):2575-2584. PubMed ID: 35587650
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.
Adekunle OA; Seoane-Vazquez E; Brown LM
J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276
[TBL] [Abstract][Full Text] [Related]
13. Advances with androgen deprivation therapy for prostate cancer.
Yu EM; Aragon-Ching JB
Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
[TBL] [Abstract][Full Text] [Related]
14. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
[TBL] [Abstract][Full Text] [Related]
15. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tutrone R; Saad F; George DJ; Tombal B; Bailen JL; Cookson MS; Saltzstein DR; Hanson S; Brown B; Lu S; Fallick M; Shore ND
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38143206
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
De La Cerda J; Dunshee C; Gervasi L; Sieber P; Belkoff L; Tutrone R; Lu S; Gatoulis SC; Brown B; Migoya E; Shore N
Target Oncol; 2023 May; 18(3):383-390. PubMed ID: 37060432
[TBL] [Abstract][Full Text] [Related]
17. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
18. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer.
Saad F; George DJ; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Tombal B; Shore ND
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835548
[No Abstract] [Full Text] [Related]
19. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
